Monday May 13
Lexicon responds to concerns over drug trial partnership
The Woodlands-based Lexicon Pharmaceuticals Inc. released its first quarter earnings May 10 and allayed some concerns over a partnership with a large pharmaceutical company before it begins Phase III trials of its diabetes drug, known as LX4211, later this year.
Monday May 13
Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
Lexicon Pharmaceuticals, Inc. announced today that Arthur Sands, M.D., Ph.D., president and chief executive officer, will present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, at 3:00 PM PDT in Las Vegas, Nevada.
Wall St. Cheat Sheet
Lexicon Pharmaceuticals Earnings Call Nuggets: Partnership Talks Update and Carcinoid Enrollment
Lexicon Pharmaceuticals recently reported its first quarter earnings and discussed the following topics in its earnings conference call.
Lexicon Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thank you for holding. Welcome to the Lexicon Pharmaceuticals' First Quarter 2013 Conference Call.
Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes
Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes , having successfully completed the open-label, pioneer portion of the trial.